tuneTypical Dose
1.0–3.0 g/day
Amino Acid
Acetyl L-Carnitine
(R)-3-acetyloxy-4-trimethylammonio-butanoate
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
Weeks to months. Not validated for immediate performance uplift.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Acetyl L-carnitine is a carnitine derivative with the clearest human evidence in diabetic peripheral neuropathy plus narrower signals in fatigue and depressive-symptom settings.
The modern human evidence supports acetyl L-carnitine more for selected clinical neuropathy and mood or fatigue contexts than for broad cognition marketing. A 2024 phase 3 diabetic-neuropathy trial strengthened the neuropathy case, while rigorous Alzheimer disease data remain negative. Minority findings include adjunctive depressive-symptom benefit and combination-formula male-fertility support, but those do not justify a general nootropic framing.
Acetyl-L-carnitine may support mitochondrial and acetyl-group metabolic pathways in neural and peripheral tissues. Clinical relevance depends heavily on population and endpoint.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Reduce fatigue and improve fatigue-related function in selected older adults. No clear cognitive decline slowing in rigorously designed AD trial.
Secondary Outcomes
- Improve forward/total motile sperm metrics in one 3-month oligoasthenozoospermia RCT. Neuropathic pain signal not superior to comparator and no placebo confirmation.
Safety
Contraindications and Interactions
Contraindications
- Pregnancy
- Lactation
- Severe psychiatric instability
- Active severe liver/renal/cardiac disease
- Active malignancy
- Sports competition without updated compliance checks
Side effects
- Nausea
- Stomach upset
- Restlessness
- Fishy body odor
Interactions
- Neuroactive agents
- Anticoagulants
- Stimulant-heavy stacks
Avoid if
- Major unstable endocrine disease
- High-risk cardiovascular profiles without clinician oversight
- Unverified high-dose supplement products
Evidence
Study-level References
acetyl-l-carnitine-SRC-001Randomized controlled trial
Sourceopen_in_newPMID: 17658628, DOI: 10.1016/j.archger.2007.03.012
Population: 96 adults >70 with fatigue criteria (Holmes major/Fukuda minor); 50 female/46 male
Dose protocol: Oral ALCAR, trial duration 3 months (dose not in PubMed abstract)
Key findings: Favorable for self-reported physical and mental fatigue, functional status and some cognitive measures (statistically significant scale improvements). Trial reported reductions in fatigue scores and improved function versus control at end-point. Baseline and protocol details require full-text confirmation for dosing context.
Notes: Older single-region RCT with historical controls in older literature. Reporting gaps around exact regimen in abstract.
Paper content
favorable for self-reported physical and mental fatigue, functional status and some cognitive measures (statistically significant scale improvements) Trial reported reductions in fatigue scores and improved function versus control at end-point; baseline and protocol details require full-text confirmation for dosing context.
acetyl-l-carnitine-SRC-002Multicenter double-blind placebo-controlled randomized trial
Sourceopen_in_newPMID: 10994000, DOI: 10.1212/wnl.55.6.805
Population: Adults 45–65 with probable early-onset AD (MMSE 12–26)
Dose protocol: ALCAR 1 g three times daily, 1 year
Key findings: Null for primary outcomes (ADAS-Cog, CDR, ADL). No clear disease-modifying signal in intent-to-treat. No significant between-group differences on primary outcomes. Adverse events similar across groups.
Notes: Strong randomization/reporting structure, but negative primary effects reduce confidence in benefit claims.
Paper content
null for primary outcomes (ADAS-Cog, CDR, ADL); no clear disease-modifying signal in intent-to-treat No significant between-group differences on primary outcomes; adverse events similar across groups.
acetyl-l-carnitine-SRC-003Randomized controlled trial (multigroup comparator)
Sourceopen_in_newPMID: 16281510 (no DOI listed)
Population: 150 men with oligoasthenozoospermia
Dose protocol: L-carnitine 2 g/day + ALCAR 1 g/day, orally, twice daily for 3 months
Key findings: Moderate-positive. Forward/total motile sperm improved significantly, pregnancy rate higher than control. Significant increase in motile parameters and higher pregnancy proportion. Forward motile/total motile improvements reached significance, while some secondary counts were mixed.
Notes: No side effects reported, but single-language/region trial and incomplete replication framework.
Paper content
moderate-positive; forward/total motile sperm improved significantly, pregnancy rate higher than control Significant increase in motile parameters and higher pregnancy proportion; forward motile/total motile improvements reached significance, while some secondary counts were mixed.
acetyl-l-carnitine-SRC-004Randomized, double-blind comparative trial (active comparator)
Sourceopen_in_newPMID: 18598095, DOI: 10.2165/00044011-200828080-00004
Population: 64 patients with moderate sciatica from herniated disc
Dose protocol: ALCAR 1180 mg/day vs thioctic acid 600 mg/day, 60 days
Key findings: Uncertain/weak. Improvements seen but no significant superiority versus active comparator. Symptom scales improved in both groups. Comparator had significantly better mean change on some endpoints.
Notes: Lacked placebo control and had limited sample size.
Paper content
uncertain/weak; improvements seen but no significant superiority versus active comparator Symptom scales improved in both groups; comparator had significantly better mean change on some endpoints.
acetyl-l-carnitine-SRC-005Systematic review (double-blind RCTs in dementia)
Sourceopen_in_newCochrane Database Syst Rev 2003 Issue 2; DOI: 10.1002/14651858.CD003158
Population: Mild-to-moderate dementia/MCI cohorts
Dose protocol: Synthesized multiple RCTs (often 1.5-3 g/day, 3-12 months in included studies)
Key findings: Mostly null for clinically meaningful outcomes. Limited/no routine use recommendation. No evidence of routine clinical benefit on cognition severity or functional outcomes. Any apparent CGI/MMSE signals were inconsistent.
Notes: Heterogeneity and trial quality concerns across included studies.
Paper content
mostly null for clinically meaningful outcomes; limited/no routine use recommendation No evidence of routine clinical benefit on cognition severity or functional outcomes; any apparent CGI/MMSE signals were inconsistent.
acetyl-l-carnitine-SRC-006Meta-analysis of double-blind RCTs (MCI/mild AD)
Sourceopen_in_newPMID: 12598816, DOI: 10.1097/00004850-200303000-00001
Population: Mild cognitive impairment and mild AD
Dose protocol: Trials with 1.5-3.0 g/day and 3 months or more duration
Key findings: Small positive pooled effect sizes on combined psychometric/clinical scales. High heterogeneity suggests effect estimates are directionally favorable in selected analyses but clinically uncertain due to variable instruments and study quality.
Notes: Broad outcome harmonization and sponsorship patterns introduce interpretation risk.
Paper content
small positive pooled effect sizes on combined psychometric/clinical scales; high heterogeneity Suggests effect estimates are directionally favorable in selected analyses but clinically uncertain due to variable instruments and study quality.
acetyl-l-carnitine-SRC-007Systematic review and meta-analysis.
Sourceopen_in_newVeronese N, Stubbs B, Solmi M, Ajnakina O, Carvalho AF, Maggi S. Acetyl-L-Carnitine Supplementation and the Treatment of Depressive Symptoms: A Systematic Review and Meta-Analysis. Psychosom Med. 2018;80(2):154-159. doi:10.1097/PSY.0000000000000537. PMID:29076953.
Population: Adults with depressive symptoms across 12 RCTs.
Dose protocol: Meta-analysis of 12 RCTs. ALC versus placebo (9 RCTs) and ALC versus antidepressants (3 RCTs).
Key findings: ALC significantly reduced depressive symptoms versus placebo (SMD = -1.10, 95% CI -1.65 to -0.56). Comparable effectiveness to antidepressants with fewer adverse effects. Effect most pronounced in older adults.
Notes: Strongest pooled evidence for ALCAR in depression. Funded by UK Department of Health. Heterogeneity across included trials warrants caution.
Paper content
This meta-analysis of 12 RCTs (791 participants, mean age 54, 65% female) found that acetyl-L-carnitine supplementation significantly reduced depressive symptoms compared to placebo (SMD = -1.10, 95% CI -1.65 to -0.56) and was comparable in efficacy to standard antidepressants (SMD = 0.06, 95% CI -0.22 to 0.34). ALC was associated with fewer adverse effects than antidepressants. The effect was most pronounced in older adults. This is the strongest pooled evidence supporting ALCAR for depressive symptoms, though heterogeneity across included trials warrants caution.
acetyl-l-carnitine-SRC-008Multicenter randomized double-blind placebo-controlled phase 3 trial
Sourceopen_in_newGuo L, Pan Q, Cheng Z, Li Z, Jiang H, Zhang F, et al. Acetyllevocarnitine Hydrochloride for the Treatment of Diabetic Peripheral Neuropathy: A Phase 3 Randomized Clinical Trial in China. Diabetes. 2024. doi:10.2337/db23-0377. PMID:38320260.
Population: Adults with type 2 diabetes and diabetic peripheral neuropathy in China.
Dose protocol: Acetyllevocarnitine hydrochloride 1500 mg/day for 24 weeks versus placebo.
Key findings: Phase 3 trial showed larger improvement in overall clinical neuropathy score versus placebo, but pain-specific separation did not clearly reach significance.
Notes: Best current neuropathy modernization source for acetyl L-carnitine. Useful for replacing vague nerve-support language with a narrower diabetic-neuropathy framing.
Paper content
This phase 3 neuropathy trial materially strengthens the modern acetyl-L-carnitine evidence base. Over 24 weeks, 1.5 g/day improved the overall clinical neuropathy score versus placebo in adults with type 2 diabetes, but the pain-specific component did not clearly separate. That supports a narrower neuropathy-function framing rather than a strong analgesic claim.